首页工具

登录

搜索结果

Search Results for " mutated "

Targets Recommended: EGFR

62

抑制剂 & 化合物

2

天然产物

65

重组蛋白

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T16162	Mutated EGFR-IN-1 Osimertinib analog,AZD9291中间体1	EGFR	Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors
	Mutated EGFR-IN-1 (Osimertinib analog) 是用于突变 EGFR 抑制剂设计的有用中间体，例如 L858R EGFR、Exon19 缺失激活突变体和 T790M 抗性突变体。
T12130	Mutated EGFR-IN-2	EGFR	Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors
	Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR.
T12131	Mutated EGFR-IN-3	EGFR	Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors
	Mutated EGFR-IN-3 is a ATP-competitive and highly selective allosteric dibenzodiazepinone EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) inhibitor(IC50 of 12 nM and 13 nM, respectively. )
T5175	azd1390	ATM/ATR	DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling
	AZD1390 是一种可口服的，可渗透脑的ATM 高度选择性抑制剂，IC50为 0.78 nM。
T6770	AZD0156	Apoptosis; ATM/ATR	Apoptosis; DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling
	AZD0156 是一种口服活性 ATM 选择性抑制剂，IC50为 0.58 nM。它抑制 ATM 介导的信号转导，防止 DNA 损伤检查点激活，破坏 DNA 损伤修复，起抗肿瘤作用。
T1821	CGK733 CGK 733	ATM/ATR	DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling
	CGK733 (CGK 733) 是一种有效的选择性 ATM/ATR 抑制剂，用于癌症研究。
T1958	AZ20	ATM/ATR; mTOR	DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling
	AZ20 是一种有效且特异性的 ATR 激酶抑制剂，IC50值为 5 nM。它还抑制mTOR 活性，IC50值为 38 nM。
T4443	AZ32	ATM/ATR	DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling
	AZ32 是一种口服生物利用度和血脑屏障穿透性 ATM 抑制剂，对 ATM 酶的 IC50 <6.2 nM，对细胞内 ATM 的 IC50 为 0.31 μM。
T6734	WZ8040	EGFR	Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors
	WZ8040 是一种新型突变选择性不可逆 EGFRT790M 抑制剂，可抑制EGFR 磷酸化。它对突变型EGFR 的活性是野生型EGFR 的100倍以上。
T6261	CP-466722 CP 466722,CP466722	ATM/ATR	DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling
	CP-466722 是一种有效且可逆的 ATM 抑制剂，IC50值为 4.1 μM。它不会抑制细胞中的 ATR 和 PI3K 或 PIKK 家族成员。
T3338	Ceralasertib AZD6738	ATM/ATR	DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling
	Ceralasertib (AZD6738) 是一种具有口服活性的选择性 ATR 激酶抑制剂，IC50 为 1 nM。
T2084	ETP-46464	ATM/ATR; DNA-PK; PI3K; mTOR	DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling
	ETP-46464 是一种有效且特异性的 ATR 抑制剂，IC50为 25 nM。
T3032	VE-821 ATR Inhibitor IV	ATM/ATR	DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling
	VE-821 (ATR Inhibitor IV) 是一种有效的 ATP 竞争性的ATR 抑制剂，Ki 为 13 nM，IC50为 26 nM。
T2685	KU-55933 ATM Kinase Inhibitor	ATM/ATR; DNA-PK; PI3K; mTOR; Autophagy	Autophagy; DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling
	KU-55933 (ATM Kinase Inhibitor) 是一种 ATM 抑制剂，IC50和 Ki 值分别为 12.9 和 2.2 nM。它对 ATM 的选择性比对 PI3K/PI4K、 DNA-PK、ATR 和 mTOR 高。
T6612	NU6027	ATM/ATR; DNA-PK; CDK	Cell Cycle/Checkpoint; DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling
	NU6027 是一种有效的 ATR/CDK 抑制剂，抑制 CDK1/2、ATR 和 DNA-PK，Ki 为 2.5 μM/1.3 μM、0.4 μM 和 2.2 μM。它以 ATR 依赖性方式增强羟基脲和顺铂的细胞毒性。
T7318	Elimusertib BAY-1895344	ATM/ATR	DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling
	Elimusertib (BAY-1895344) 是一种可口服的选择性ATR 抑制剂，IC50值为 7 nM。它具有抗肿瘤活性，可研究实体瘤和淋巴瘤。
T7122	AZD-7648	DNA-PK	DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling
	AZD-7648 是一种 DNA 依赖性蛋白激酶 (DNA-PK) 抑制剂，在酶试验中 IC50 为 0.63 nM，具有抗肿瘤活性。
T14511	BAY1082439 N-[8-[[(2R)-2-羟基-3-(吗啉-4-基)丙基]氧基]-7-甲氧基-2,3-二氢咪唑并[1,2-C]喹唑啉-5-基]-2-甲基吡啶-3-甲酰胺	Apoptosis; PI3K	Apoptosis; PI3K/Akt/mTOR signaling
	BAY1082439 是一种具有口服活性的，选择性 PI3Kα/β/δ抑制剂。它也能抑制 PIK3CA 的突变形式，它对抑制 Pten 丢失的前列腺癌的生长有很强的作用。
T6487	Encorafenib LGX818	Raf	MAPK
	Encorafenib (LGX818) 是一种可口服的突变型 BRaf V600E 抑制剂，IC50为 0.3 nM，具有潜在的抗肿瘤活性。
T2705	Mutant EGFR inhibitor	EGFR	Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors
	Mutant EGFR inhibitor 是选择性EGFR 突变体抑制剂，可抑制EGFRL858R、EGFRExon 19 deletion 和EGFRT790M。
T9303	MRTX1133	Ras	GPCR/G Protein; MAPK
	MRTX1133 是一种 KRAS G12D 抑制剂 (KD=0.2 pM)，具有强效性、选择性和非共价性。MRTX1133 对 KRAS G12D 突变的肿瘤具有抑制活性，而对 KRAS 野生型肿瘤无抑制活性。
T3579	PLX8394	Raf	MAPK
	PLX8394 是一种口服活性的丝氨酸/苏氨酸蛋白激酶 B-Raf (BRAF) 蛋白抑制剂。 PLX8394 可以选择性地结合并抑制野生型和突变形式的 BRAF 的活性，然后抑制表达 BRAF 突变形式的肿瘤细胞的增殖。 PLX8394 似乎对表达多种激酶突变形式的肿瘤有效，并且可能是对其他对 BRAF V600E 突变体特异的 BRAF 抑制剂疗法耐药的肿瘤的有效治疗剂。
T8882	Vodobatinib K-0706	Bcr-Abl	Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors
	Vodobatinib (K-0706) 是第三代具有口服活性的Bcr-Abl1酪氨酸激酶抑制剂，IC50=7 nM，对大多数 BCR-ABL1 点突变体具有活性，但对 BCR-ABL1T315I 无活性。它可用于研究慢性粒细胞白血病 (CML)。
T9473	4SC-203	FLT	Angiogenesis; Tyrosine Kinase/Adaptors
	4SC-203 是一种具有潜在的抗肿瘤活性的多激酶抑制剂。它对 FLT3/STK1、 FLT3 的突变形式以及 VEGFRs 具有选择性抑制作用。
T1903	Dabrafenib GSK2118436A,GSK2118436,达拉非尼	Raf	MAPK
	Dabrafenib (GSK2118436A) 是一种 Raf 抑制剂，抑制 C-Raf 和 B-RafV600E (IC50=5/0.6 nM)，具有 ATP 竞争性。Dabrafenib 具有抗肿瘤活性，可用于治疗 B-RafV600E 突变的黑色素瘤。
T9856	FLT3-IN-10 2-Oxazolamine, 5-(4-fluorophenyl)-N-phenyl-	FLT	Angiogenesis; Tyrosine Kinase/Adaptors
	FLT3-IN-10 (2-Oxazolamine, 5-(4-fluorophenyl)-N-phenyl-) (compound 7c) 是有效的 FMS 样酪氨酸激酶 3 (FLT3) 抑制剂。FLT3-IN-10 具有治疗 FLT3 突变的急性髓性白血病 (AML) 的潜力。
T3024	Avitinib AC0010,艾维替尼	EGFR; JAK; BTK	Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors
	Avitinib (AC0010) 是一种不可逆的、突变体选择性的EGFR 抑制剂，可有效抑制非小细胞肺癌中EGFR T790M 耐药突变。阿比替尼也是一种新型BTK 抑制剂。
T13884	Shield-1	Others	Others
	Shield-1 是 FK506 结合蛋白 12 (FKBP) 的特异性、高亲和力和细胞渗透性配体，通过与突变的 FKBP (mtFKBP) 结合来逆转不稳定性，允许 mtFKBP 融合蛋白的条件表达。它可以稳定整个融合蛋白。
T2307	Icotinib Hydrochloride 埃克替尼盐酸盐,盐酸埃克替尼,BPI-2009H	EGFR	Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors
	Icotinib Hydrochloride (BPI-2009H) 是一种口服的基于喹唑啉的表皮生长因子受体 (EGFR) 抑制剂，IC50值为5 nM，具有潜在的抗肿瘤活性。
T2490	Osimertinib AZD-9291,Mereletinib,奥希替尼	EGFR	Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors
	Osimertinib (AZD-9291) 是一种 EGFR 三代抑制剂，抑制二代 EGFR 抑制剂产生的 T790M 耐药突变，具有不可逆性和口服活性。Osimertinib 具有抗肿瘤活性，用于治疗 EGFR 突变的非小细胞肺癌。
T3617	Ivosidenib 艾伏尼布,AG-120	Dehydrogenase; Isocitrate Dehydrogenase (IDH)	Metabolism
	Ivosidenib (AG-120) 是一种口服具有活力的异柠檬酸脱氢酶 1 的突变体酶 (mIDH1 enzyme) 抑制剂，能够使 d-2- hydroxyglutatrate (2-HG) 在体内降低。它具有良好的的安全性和临床活性，具有研究 AML 的潜力。
T0373	Erlotinib OSI-744,NSC 718781,CP358774,埃罗替尼,R1415	EGFR; Autophagy	Angiogenesis; Autophagy; JAK/STAT signaling; Tyrosine Kinase/Adaptors
	Erlotinib (CP358774) 是一种 EGFR 一代抑制剂，抑制 EGFR 19 Del 和 L858R 突变。Erlotinib 具有抗肿瘤活性，用于治疗 EGFR 突变的非小细胞肺癌。Erlotinib 用药会产生 EGFR C797S 耐药突变。
T34916	Transtinib	Others	Others
	Transtinib is an effective and irreversible EGFR tyrosine kinase inhibitor (EGFR-TKI) that is active against L858R/T790M mutated NSCLC cell lines and xenografts.
T70133	BAY-846	Others	Others
	BAY-846 is an allosteric MEK inhibitor with long half-lives, high bioavailabilities, low brain penetration potential and high efficacy in a K-Ras-mutated A549 xenograft model.
T71037	BAY-438	Others	Others
	BAY-438 is an allosteric MEK inhibitor with long half-lives, high bioavailabilities, low brain penetration potential and high efficacy in a K-Ras-mutated A549 xenograft model.
T13627	CP-10	CDK; PROTACs	Cell Cycle/Checkpoint; PROTAC
	CP-10 is a PROTAC with highly selective and remarkable CDK6 degradation (DC50: 2.1 nM). It inhibits the proliferation of several hematopoietic cancer cells including multiple myeloma and can degrade mutated and overexpressed CDK6.
T39523	Antitumor agent-28	Others	Others
	Antitumor agent-28 is a compound that specifically targets and inhibits the activity of the ataxia telangiectasia mutated (ATM) kinase. By doing so, it effectively impedes the progression of ATM-mediated diseases and demonstrates significant anti-cancer activity.
T78711	A011	ATM/ATR	DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling
	A011，作为一种选择性的ataxia-telangiectasia mutated (ATM)抑制剂，其IC50为1.0 nM，能够在与CPT-11联合应用时，诱导Apoptosis及G2/M期细胞周期阻滞，显示出显著的抗肿瘤活性。
T66481	TG-693	Others	Others
	TG693, an orally available inhibitor of CLK1, promotes the skipping of the endogenous mutated exon 31 in Duchenne muscular dystrophy (DMD) patient-derived cells and increased the production of the functional exon 31-skipped dystrophin protein.
T40212	ATR-IN-4	Others	Others
	ATR-IN-4, a potent inhibitor of ATR (Ataxia telangiectasia mutated gene Rad 3-associated kinase), restricts the growth of DU145 prostate cancer cells and NCI-H460 lung cancer cells, with IC 50 values of 130.9 nM and 41.33 nM, respectively.
T36245	SJF 1528	Others	Others
	Potent EGFR Degrader (DC50 values are 39.2 nM for wild-type EGFR in OVCAR8 cells and 736 nM for Exon20Ins mutated EGFR in HeLa cells). Also degrades HER2. Comprises the EGFR inhibitor lapatinib (Cat. No. 6811) joined by a linker to a von Hippel-Lindau (VHL) recruiting ligand. Inhibits proliferation of HER2-driven breast cancer cell lines (IC50 = 102 nM for SKBr3 cells).
T37661	LY 2886721 Hydrochloride	Others	Others
	Potent and selective β-secretase (BACE) inhibitor (IC50 values are 10.2 and 20.3 nM for human BACE2 and BACE1, respectively). Displays >5,000-fold selectivity for BACE over other proteases including cathepsin D, pepsin and renin. Inhibits Aβ1-40 and Aβ1-42 production in cells expressing mutated APP. Reduces hippocampal and cortical Aβ and sAPPβ levels in an Alzheimer's disease mouse model.
T68895	CBP-93872	Others	Others
	CBP-93872 is a G2 checkpoint inhibitor. CBP-93872 specifically abrogates the DNA double-stranded break (DSB)-induced G2 checkpoint through inhibiting maintenance. CBP-93872 is an inhibitor of maintenance of the DSB-specific G2 checkpoint and thus might be a strong candidate as the basis for a drug that specifically sensitizes p53-mutated cancer cells to DSB-inducing DNA damage therapy.
T74707	PROTAC FLT3/CDK9 degrader-1	Others	Others
	PROTACFLT3/CDK9 degrader-1 是一种有效的FLT3和CDK9双PROTAC 降解剂。PROTACFLT3/CDK9 degrader-1 诱导细胞凋亡 (Apoptosis) 并有效降解靶蛋白FLT3和 CDK9。PROTACFLT3/CDK9 degrader-1具有研究 FLT3-ITD 突变型 AML 的潜力。
T39439	Seclidemstat mesylate SP-2577 mesylate	Others	Others
	Seclidemstat mesylate (SP-2577) is a highly effective and reversible inhibitor of KDM1A (LSD1), with a Ki of 31 nM and an IC 50 of 13 nM. It demonstrates significant potential in promoting antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, while also exhibiting inhibitory effects on virus production, viral DNA replication, and late gene expression. Seclidemstat mesylate is a valuable tool for studying Ewing Sarcoma in research settings.
T77082	Melredableukin alfa
	Melredableukin alfa (RO-7049665)是一种由人IgG1-κ通过多肽连接子与人突变白细胞介素2(IL2 mutin)融合形成的融合蛋白。它适用于乙型肝炎和溃疡性结肠炎的研究。
T63386	Pan-RAF kinase inhibitor 1	Others	Others
	Pan-RAF kinase inhibitor 1 是 Pan-RAF 激酶对有效抑制剂，能够抑制 RAF 激酶，调节 MAPK 信号传导，进而影响 RAS 突变肿瘤细胞的增殖。 Pan-RAF kinase inhibitor 1 对研究癌症疾病表现出研究潜力。
T71184	ARQ-736	Others	Others
	ARQ 736 is a potent and selective BRAF inhibitor. ARQ 736 is selectively potent in killing cancer cell lines harboring at least one mutated BRAF allele. BRAF mutations were detected in over 60% of melanomas and may account for a significant proportion of colon cancer patients whose tumors are resistant to anti-EGFR therapy. The B-Raf protein is a key signaling molecule in the mitogen activated protein kinase (MAPK) signaling pathway and has been implicated in the pathogenesis of a variety of ca...
T68383	BIIB028	Others	Others
	BIIB028 is a small-molecule inhibitor of heat shock protein (Hsp) 90 with potential antineoplastic activity. Hsp90 inhibitor BIIB028 blocks the binding of oncogenic client proteins to Hsp90, which may result in the proteasomal degradation of these proteins and so the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as Her2/Erbb2, Akt, Raf1, Bcr-Abl, and mutated p53, in addition to o...
T83737	LRRKtide TFA Moesin (550-564),Membrane-organizing Extension Spike Protein (550-564)
	LRRKtide是一个针对富含亮氨酸重复激酶2 (LRRK2)的肽基底物，LRRK2是在帕金森病患者中频繁发生突变的酶，对应于膜组织扩展刺突蛋白(moesin)的550-564氨基酸。该化合物用于识别LRRK2的抑制剂。

化合物

Mutated EGFR-IN-1

Cat.No: T16162

Synonym: Osimertinib analog,AZD9291中间体1

Target: EGFR

Mutated EGFR-IN-2

Cat.No: T12130

Target: EGFR

Mutated EGFR-IN-3

Cat.No: T12131

Target: EGFR

Cat.No: T5175

Target: ATM/ATR

Cat.No: T6770

Target: Apoptosis, ATM/ATR

Cat.No: T1821

Synonym: CGK 733

Target: ATM/ATR

Cat.No: T1958

Target: ATM/ATR, mTOR

Cat.No: T4443

Target: ATM/ATR

Cat.No: T6734

Target: EGFR

Cat.No: T6261

Synonym: CP 466722,CP466722

Target: ATM/ATR

Cat.No: T3338

Synonym: AZD6738

Target: ATM/ATR

Cat.No: T2084

Target: ATM/ATR, DNA-PK, PI3K, mTOR

Cat.No: T3032

Synonym: ATR Inhibitor IV

Target: ATM/ATR

Cat.No: T2685

Synonym: ATM Kinase Inhibitor

Target: ATM/ATR, DNA-PK, PI3K, mTOR, Autophagy

Cat.No: T6612

Target: ATM/ATR, DNA-PK, CDK

Cat.No: T7318

Synonym: BAY-1895344

Target: ATM/ATR

Cat.No: T7122

Target: DNA-PK

Cat.No: T14511

Synonym: N-[8-[[(2R)-2-羟基-3-(吗啉-4-基)丙基]氧基]-7-甲氧基-2,3-二氢咪唑并[1,2-C]喹唑啉-5-基]-2-甲基吡啶-3-甲酰胺

Target: Apoptosis, PI3K

Cat.No: T6487

Synonym: LGX818

Target: Raf

Mutant EGFR inhibitor

Cat.No: T2705

Target: EGFR

Cat.No: T9303

Target: Ras

Cat.No: T3579

Target: Raf

Cat.No: T8882

Synonym: K-0706

Target: Bcr-Abl

Cat.No: T9473

Target: FLT

Cat.No: T1903

Synonym: GSK2118436A,GSK2118436,达拉非尼

Target: Raf

Cat.No: T9856

Synonym: 2-Oxazolamine, 5-(4-fluorophenyl)-N-phenyl-

Target: FLT

Cat.No: T3024

Synonym: AC0010,艾维替尼

Target: EGFR, JAK, BTK

Cat.No: T13884

Target: Others

Icotinib Hydrochloride

Cat.No: T2307

Synonym: 埃克替尼盐酸盐,盐酸埃克替尼,BPI-2009H

Target: EGFR

Cat.No: T2490

Synonym: AZD-9291,Mereletinib,奥希替尼

Target: EGFR

Cat.No: T3617

Synonym: 艾伏尼布,AG-120

Target: Dehydrogenase, Isocitrate Dehydrogenase (IDH)

Cat.No: T0373

Synonym: OSI-744,NSC 718781,CP358774,埃罗替尼,R1415

Target: EGFR, Autophagy

Cat.No: T34916

Target: Others

Cat.No: T70133

Target: Others

Cat.No: T71037

Target: Others

Cat.No: T13627

Target: CDK, PROTACs

Antitumor agent-28

Cat.No: T39523

Target: Others

Cat.No: T78711

Target: ATM/ATR

Cat.No: T66481

Target: Others

Cat.No: T40212

Target: Others

Cat.No: T36245

Target: Others

LY 2886721 Hydrochloride

Cat.No: T37661

Target: Others

Cat.No: T68895

Target: Others

PROTAC FLT3/CDK9 degrader-1

Cat.No: T74707

Target: Others

Seclidemstat mesylate

Cat.No: T39439

Synonym: SP-2577 mesylate

Target: Others

Melredableukin alfa

Cat.No: T77082

Pan-RAF kinase inhibitor 1

Cat.No: T63386

Target: Others

Cat.No: T71184

Target: Others

Cat.No: T68383

Target: Others

Cat.No: T83737

Synonym: Moesin (550-564),Membrane-organizing Extension Spike Protein (550-564)

Cat. No.	Product Name	Target	Signaling Pathways
TN1673	Garcinone C 伽升沃 C,伽升沃C	ATM/ATR; CDK; STAT; AChR; Antifection	Cell Cycle/Checkpoint; DNA Damage/DNA Repair; JAK/STAT signaling; Microbiology/Virology; Neuroscience; PI3K/Akt/mTOR signaling; Stem Cells
	Garcinone C 是一种从 Garcinia oblongifolia Champ 中提取的黄酮衍生物，具有抗炎、收敛和促进肉芽的活性。 Garcinone C 是一种 AChE 抑制剂，对某些癌症具有潜在的细胞毒性作用。
T1181	Gefitinib ZD1839,吉非替尼	EGFR; Tyrosine Kinases; Autophagy	Angiogenesis; Autophagy; JAK/STAT signaling; Tyrosine Kinase/Adaptors
	Gefitinib (ZD1839) 是一种 EGFR 一代抑制剂，具有口服活性，抑制 EGFR 19 Del 和 L858R 突变。Gefitinib 具有抗肿瘤活性，用于治疗 EGFR 突变的非小细胞肺癌。Gefitinib 用药会产生 EGFR C797S 耐药突变。

天然产物

Cat.No: TN1673

Synonym: 伽升沃 C,伽升沃C

Target: ATM/ATR, CDK, STAT, AChR, Antifection

Cat.No: T1181

Synonym: ZD1839,吉非替尼

Target: EGFR, Tyrosine Kinases, Autophagy

Species：

Expression System：

Tag：

Cat. No.	Product Name	Species	Expression System
TMPH-03747	CCDC112 Protein, Human, Recombinant (His & Myc) Mutated in bladder cancer protein 1,Coiled-coil dom...	Human	E. coli
	CCDC112 Protein, Human, Recombinant (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 61.0 kDa and the accession number is Q8NEF3.
TMPY-02953	TEM8/ANTXR1 Protein, Human, Recombinant (hFc) ATR,TEM8,anthrax toxin receptor 1,GAPO	Human	HEK293 Cells
	ANTXR1 contains 1 VWFA domain and belongs to the ATR family. ATR (Ataxia telangiectasia and Rad3 related) and ATM (Ataxia telangiectasia mutated) are closely related kinases that are activated by DNA damage. They are serine-threonine protein kinases and belongs to the phosphatidylinositol 3' kinase-like kinase (PIKK) family. Upon recruitment by the DNA damage binding proteins/complexes (ATRIP for ATR; MRN for ATM), ATM/ATR initiate the DNA damage checkpoint by phosphorylating a number of key pro...
TMPY-04548	CDK4 Protein, Human, Recombinant (GST) CMM3,PSK-J3,cyclin-dependent kinase 4	Human	Baculovirus Insect Cells
	CDK4 is a member of the Ser/Thr protein kinase family. It is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of CDK4 is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). CDK4 was shown to be responsible for the phosphorylation of retinoblastoma gene product. CDK4 is the ser...
TMPK-01399	HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated K-RAS2A,NS3,KRAS2,CFC2,K-RAS4B,GTPase Kras,RALD,MHC,KRAS,RAS...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01479	HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated NS3,KRAS1,K-Ras 2,K-RAS2A,K-RAS2B,C-K-RAS,K-RAS4A,CFC2,KRAS2...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01510	HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi) NS,NS3,KRAS2,RASK2,MHC,RALD,K-Ras 2,K-RAS4B,C-K-RAS,KI-RAS,K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01401	HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi) MHC,CFC2,K-Ras 2,RALD,K-RAS4A,NS,RASK2,GTPase Kras,K-RAS2B,K...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01488	HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi) K-RAS4A,MHC,GTPase Kras,K-Ras 2,KRAS2,K-RAS2B,CFC2,RASK2,RAL...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01511	HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated GTPase Kras,K-RAS4A,KI-RAS,K-RAS4B,C-K-RAS,K-Ras 2,RASK2,K-R...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01489	HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi) K-RAS2A,NS3,KRAS1,KRAS2,MHC,NS,K-RAS2B,K-RAS4A,KRAS,CFC2,RAS...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01400	HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated NS,KRAS1,RALD,K-RAS2A,K-RAS2B,K-RAS4A,MHC,RASK2,KRAS,GTPase ...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01471	HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled CFC2,KRAS,K-RAS4B,MHC,K-RAS2B,KRAS1,NS3,K-RAS2A,NS,K-RAS4A,R...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01407	HLA-A*02:01&B2M&KRAS WT (KLVVVGAGGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated KRAS2,RALD,C-K-RAS,NS3,MHC,CFC2,KRAS,KI-RAS,K-RAS4B,NS,K-RAS...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01512	HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi) K-Ras 2,NS,NS3,K-RAS2B,CFC2,MHC,KRAS1,GTPase Kras,K-RAS4A,KR...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01438	HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled RASK2,KRAS2,KRAS1,MHC,C-K-RAS,KI-RAS,K-RAS4B,RALD,K-RAS4A,NS...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPH-01578	KRT18 Protein, Human, Recombinant (His) Keratin, type I cytoskeletal 18,KRT18,Cell proliferation-ind...	Human	HEK293 Cells
	Involved in the uptake of thrombin-antithrombin complexes by hepatic cells. When phosphorylated, plays a role in filament reorganization. Involved in the delivery of mutated CFTR to the plasma membrane. Together with KRT8, is involved in interleukin-6 (IL-6)-mediated barrier protection.
TMPK-01404	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated NS,KRAS,KRAS1,KRAS2,MHC,RALD,K-RAS4A,K-RAS2A,K-RAS4B,K-RAS2B...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01434	HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi) RASK2,CFC2,GTPase Kras,KRAS,K-RAS2B,MHC,K-RAS2A,K-RAS4A,KRAS...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01525	HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated CFC2,RALD,K-Ras 2,MHC,C-K-RAS,NS3,GTPase Kras,KRAS2,K-RAS4B,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01403	HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi) K-Ras 2,KI-RAS,CFC2,KRAS1,GTPase Kras,KRAS,K-RAS4B,RALD,NS3,...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01461	HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi) C-K-RAS,KRAS,RASK2,K-Ras 2,K-RAS2A,MHC,CFC2,K-RAS4B,K-RAS2B,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01427	HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated C-K-RAS,K-RAS4B,GTPase Kras,K-RAS4A,K-RAS2A,KRAS2,CFC2,RASK2...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01463	HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi) C-K-RAS,KI-RAS,KRAS1,K-RAS4A,KRAS2,CFC2,MHC,NS3,K-RAS2B,NS,K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01429	HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated MHC,K-Ras 2,NS,K-RAS4A,KRAS,NS3,KI-RAS,K-RAS2A,K-RAS2B,RALD,...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01518	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi) MHC,NS,KRAS1,K-RAS2A,GTPase Kras,KRAS,RALD,KRAS2,RASK2,C-K-R...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01527	HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi) NS,RALD,C-K-RAS,RASK2,K-RAS2B,KRAS2,KRAS,K-RAS2A,K-RAS4A,KRA...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01408	HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated RALD,KRAS1,KRAS2,K-RAS2B,CFC2,NS3,GTPase Kras,MHC,K-RAS2A,KI...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01433	HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi) GTPase Kras,NS3,K-Ras 2,K-RAS2B,RALD,MHC,RASK2,K-RAS4A,CFC2,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01458	HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi) K-Ras 2,GTPase Kras,KRAS2,MHC,K-RAS4A,CFC2,K-RAS2A,KRAS1,RAS...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01451	HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi) NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,CFC2,K-RA...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01529	HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi) K-RAS4A,KRAS1,MHC,K-RAS2B,CFC2,GTPase Kras,K-RAS4B,KRAS2,NS3...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01462	HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated K-RAS4A,K-RAS2A,CFC2,KRAS1,K-RAS4B,C-K-RAS,KRAS,K-RAS2B,K-Ra...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01450	HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS2B,K-Ras 2,C-K-RAS,RASK2,K-...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01405	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi) KI-RAS,RASK2,K-Ras 2,MHC,KRAS,KRAS1,NS3,K-RAS2A,K-RAS2B,GTPa...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01460	HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated MHC,K-RAS2A,KI-RAS,K-RAS4B,RALD,NS3,GTPase Kras,K-RAS2B,C-K-...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01428	HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi) CFC2,K-RAS4B,K-Ras 2,C-K-RAS,RASK2,NS3,RALD,KI-RAS,K-RAS2A,M...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01443	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled KRAS1,C-K-RAS,K-RAS4B,RALD,K-Ras 2,K-RAS2A,K-RAS2B,KRAS2,NS3...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01526	HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi) KRAS,NS3,GTPase Kras,RASK2,K-RAS2B,C-K-RAS,MHC,KRAS2,KI-RAS,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01490	HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi) K-RAS2A,GTPase Kras,K-Ras 2,RALD,KRAS2,K-RAS4A,MHC,K-RAS4B,C...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01453	HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated RASK2,CFC2,K-Ras 2,NS3,GTPase Kras,KRAS1,K-RAS4B,K-RAS2B,MHC...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01464	HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated C-K-RAS,K-RAS4A,GTPase Kras,K-RAS2A,NS,K-RAS2B,MHC,KRAS2,K-R...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01537	HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated K-RAS4A,NS,C-K-RAS,RALD,GTPase Kras,K-RAS2A,K-RAS4B,CFC2,RAS...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01536	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated NS3,MHC,KRAS,RALD,CFC2,K-RAS2B,GTPase Kras,K-Ras 2,K-RAS2A,K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01457	HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated K-Ras 2,CFC2,RALD,MHC,KRAS,K-RAS4B,NS3,C-K-RAS,NS,KI-RAS,K-R...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01431	HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer Protein, Human, MHC (His & Avi) RALD,C-K-RAS,MHC,K-RAS2A,GTPase Kras,KRAS,NS,RASK2,K-RAS4B,K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01439	HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled KRAS,GTPase Kras,K-RAS2A,K-RAS4A,NS,CFC2,RALD,MHC,C-K-RAS,NS...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01440	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled RASK2,KI-RAS,C-K-RAS,KRAS,MHC,NS,K-RAS4A,K-RAS2B,CFC2,K-Ras ...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01432	HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi) RASK2,K-RAS4A,K-RAS4B,KRAS2,CFC2,MHC,KRAS,KI-RAS,K-RAS2B,C-K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01435	HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled KRAS2,NS3,RASK2,KI-RAS,RALD,K-RAS2B,K-RAS4B,GTPase Kras,C-K-...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01430	HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi) K-RAS2A,RALD,NS3,K-Ras 2,KI-RAS,NS,MHC,K-RAS2B,K-RAS4A,KRAS1...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
------------------------ 更多 ------------------------

重组蛋白

CCDC112 Protein, Human, Recombinant (His & Myc)

Cat.No: TMPH-03747

Species: Human

Expression System: E. coli

TEM8/ANTXR1 Protein, Human, Recombinant (hFc)

Cat.No: TMPY-02953

Species: Human

Expression System: HEK293 Cells

CDK4 Protein, Human, Recombinant (GST)

Cat.No: TMPY-04548

Species: Human

Expression System: Baculovirus Insect Cells

HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01399

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01479

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01510

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

Cat.No: TMPK-01401

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01488

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01511

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01489

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

Cat.No: TMPK-01400

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled

Cat.No: TMPK-01471

Species: Human

Expression System: HEK293 Cells

HLA-A*02:01&B2M&KRAS WT (KLVVVGAGGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01407

Species: Human

Expression System: E. coli

HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01512

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

Cat.No: TMPK-01438

Species: Human

Expression System: HEK293 Cells

KRT18 Protein, Human, Recombinant (His)

Cat.No: TMPH-01578

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

Cat.No: TMPK-01404

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01434

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01525

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

Cat.No: TMPK-01403

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01461

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01427

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01463

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

Cat.No: TMPK-01429

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01518

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01527

Species: Human

Expression System: HEK293 Cells

HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01408

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01433

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01458

Species: Human

Expression System: HEK293 Cells

HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01451

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01529

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01462

Species: Human

Expression System: HEK293 Cells

HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01450

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

Cat.No: TMPK-01405

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01460

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01428

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled

Cat.No: TMPK-01443

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01526

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01490

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01453

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01464

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01537

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01536

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01457

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01431

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

Cat.No: TMPK-01439

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

Cat.No: TMPK-01440

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01432

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

Cat.No: TMPK-01435

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

Cat.No: TMPK-01430

Species: Human

Expression System: E. coli

--------- 更多 ---------

我们的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

Copyright © 2015-2024 TargetMol Chemicals Inc. All rights reserved. 沪ICP备20019793号-4

沪公网安备 31010602006700号

沪公网安备 31010602006700号

TargetMol Loading

联系我们

电话：

400-820-0310

邮箱：

service@tsbiochem.com

QQ：

2881945090（终端用户）

2885109491（经销商）

经销：

终端：

地址：

上海市静安区江场三路238号8楼